A A A

Llame al (877) 436-3683

In English >

  • Cómo le Ayudamos
  • Formularios y Documentos
  • Preguntas Frecuentes

In English >

  • ACTEMRA® (tocilizumab)‎
  • ALECENSA® (alectinib)
  • AVASTIN® (bevacizumab)
  • COTELLIC® (cobimetinib)
  • ENSPRYNG™ (satralizumab-mwge)
  • ERIVEDGE® (vismodegib)
  • ESBRIET® (pirfenidone)
  • Evrysdi™ (risdiplam)
  • GAZYVA® (obinutuzumab)
  • HEMLIBRA® (emicizumab-kxwh)
  • HERCEPTIN® (trastuzumab)
  • Herceptin HYLECTA™ (trastuzumab and hyaluronidase-oysk)
  • KADCYLA® (ado-trastuzumab emtansine)
  • LUCENTIS® (ranibizumab injection)
  • OCREVUS® (ocrelizumab)
  • PERJETA® (pertuzumab)
  • PHESGO™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf)
  • POLIVY® (polatuzumab vedotin-piiq)
  • PULMOZYME® (dornase alfa) Inhalation Solution
  • RITUXAN® (rituximab)
  • RITUXAN HYCELA® (rituximab/hyaluronidase human)
  • ROZLYTREK™ (entrectinib)
  • TECENTRIQ® (atezolizumab)
  • VENCLEXTA® (venetoclax tablets)
  • XELODA® (capecitabine)
  • XOLAIR® (omalizumab) for subcutaneous use
  • ZELBORAF® (vemurafenib)
  • ONCOLOGY
  • RHEUMATOLOGY

Seleccione el tratamiento para continuar

  • ACTEMRA® (tocilizumab)‎
  • ALECENSA® (alectinib)
  • AVASTIN® (bevacizumab)
  • COTELLIC® (cobimetinib)
  • ENSPRYNG™ (satralizumab-mwge)
  • ERIVEDGE® (vismodegib)
  • ESBRIET® (pirfenidone)
  • Evrysdi™ (risdiplam)
  • GAZYVA® (obinutuzumab)
  • HEMLIBRA® (emicizumab-kxwh)
  • HERCEPTIN® (trastuzumab)
  • Herceptin HYLECTA™ (trastuzumab and hyaluronidase-oysk)
  • KADCYLA® (ado-trastuzumab emtansine)
  • LUCENTIS® (ranibizumab injection)
  • OCREVUS® (ocrelizumab)
  • PERJETA® (pertuzumab)
  • PHESGO™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf)
  • POLIVY® (polatuzumab vedotin-piiq)
  • PULMOZYME® (dornase alfa) Inhalation Solution
  • RITUXAN® (rituximab)
  • RITUXAN HYCELA® (rituximab/hyaluronidase human)
  • ROZLYTREK™ (entrectinib)
  • TECENTRIQ® (atezolizumab)
  • VENCLEXTA® (venetoclax tablets)
  • XELODA® (capecitabine)
  • XOLAIR® (omalizumab) for subcutaneous use
  • ZELBORAF® (vemurafenib)
  • O SELECCIONE

  • ONCOLOGY
  • RHEUMATOLOGY

Seleccione el tratamiento para continuar

Seleccione su problema de salud para Rituxan® (rituximab)

  • Rituxan® (rituximab) para Rheumatoid Arthritis (RA)
  • Rituxan® (rituximab) para Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)
  • RITUXAN® (rituximab) para Oncology
  • Rituxan® (rituximab) para Pemphigus Vulgaris (PV)
Su búsqueda no ha producido resultados.

Estamos aquí para ayudarle.

Llame al 866-422-2377

2021
  • Contacte con Nosotros
  • Mapa del Sitio
  • Política de Privacidad
  • Términos y Condiciones
  • Cookie Preferences

©[AÑO] Genentech USA, Inc. Todos los derechos reservados.  Este sitio solo está destinado a residentes en EE. UU.

El logotipo de Access Solutions es una marca registrada de Genentech, Inc.

Link to Third Party Site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Cancel OK

Link to Healthcare Professionals Site

The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.

Cancel OK

Cancel

Your email has been sent!

Thanks for sharing this page.